Vandana Singh

Vandana Singh

Benzinga Editor

About
Vandana Singh, MBA Finance is an Editor of the Benzinga Breaking News. Vandana has been covering the healthcare sector for over 10 years, including providing support services to renowned investment banks.
EXCLUSIVE: Zapata AI Partners With India-Based Tech Mahindra To Transform Network And Customer Operations
Zapata Computing partners with Tech Mahindra to revolutionize CSP solutions. Leveraging Zapata AI's quantum-based Generative AI, expect enhanced operational efficiency, proactive maintenance, and personalized customer interactions.
Will Insulet's Monopoly Crumble? Appellate Court Ruling Signals Shift in Automated Insulin Delivery Systems Market
Latest on Insulet and its legal battle with EOFlow. Understand the impact of the appellate court's decision on market dynamics and Insulet's future.
DNA Medicine Focused INOVIO Pharma Efficiencies Implemented By Leadership Will Help De-Risk Its Platform Technology: Analyst
Stephens covers INOVIO Pharmaceuticals highlighting its diverse clinical pipeline and FDA's consideration of INO-3107 Phase 1/2 trials for Accelerated Approval. Potential as the first non-surgical RRP treatment.
Indian Rival Meril Accuses Edwards Lifesciences Of Anti-Competitive Behavior In EU Antitrust Complaint
Edwards Lifesciences faces EU antitrust complaint from Meril over patent disputes, intensifying regulatory scrutiny. Recent actions aim to ensure fair competition, affordability, as Meril alleges patent abuses and obstruction to innovation.
Philips Sues SoClean Alleging Ozone Exposure Risks Over Injuries Related To Breathing Devices
Legal battle ensues between Philips and SoClean post $1.1 billion settlement over CPAP device recall. Lawsuit alleges SoClean's ozone exposure led to injuries. Philips targets DWHP, alleging SoClean as an "alter ego." FDA warns against ozone cleaners.
Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients
Phase 2a trial results of Pliant Therapeutics' bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis. Reduced lung collagen, improved FVC, and cough severity, signaling potential fibrosis reversal.
FDA Declines To Approve Expanded Use of Dynavax's Hepatitis B Vaccine In Hemodialysis Patients
Latest regulatory update from Dynavax on HEPLISAV-B vaccine regimen for adults on hemodialysis, with FDA's Complete Response Letter.
Johnson & Johnson's Subsidiary Discontinues Some Megadyne Electrodes For Pediatric Use
Johnson & Johnson's Megadyne Mega Soft Pediatric Patient Return Electrodes recalled due to patient burns. FDA's Class I recall impacts 21,200 devices.
Pfizer Follows Eli Lilly's Footsteps To Sell Medicines Directly To Patients
Pfizer seeks to expands its reach with 'Pfizer for All,' offering direct-to-consumer medical services, including COVID treatments & telehealth.
Why Is Inventiva's Stock Trading Higher on Monday?
Inventiva's Lanifibranor improves cardiometabolic health in MASH/NASH patients. It lowers fasting glucose, reduces cardiovascular risk, and increases adiponectin levels. Weight gain correlates with health improvement.
Novo Nordisk's Hemophilia Candidate Can Prevent Bleeding Episodes Effectively, Regardless Of Dosing Frequency
Novo Nordisk's Phase 3a trial demonstrates a significant reduction in bleeding episodes with Mim8 treatment for hemophilia A patients. Superior efficacy and safety profile revealed.
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
Unlocking hope for Alzheimer's with ACI-24.060. Takeda's agreement with AC Immune targets toxic forms of Abeta, potentially slowing disease progression.
Valneva Seeks Expanded Use For Its Chikungunya Vaccine In Adolescents With Encouraging Phase 3 Data
Valneva released positive Phase 3 data for its single-shot chikungunya virus vaccine in adolescents. The vaccine is also expected to be approved for use in Brazil.
Healthcare Giants Pfizer, AstraZeneca, Sanofi Inject Over $2B To Boost France's Healthcare Sector
Pfizer and AstraZeneca invest over $1 billion in France's healthcare sector, bolstering R&D capabilities and job creation.
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment
Merck halts vibostolimab and pembrolizumab coformulation arm in KeyVibe-010 Phase 3 trial for high-risk melanoma due to higher discontinuation rates and immune-related adverse events.
GameStop's Rally Resumes In May - What Sparked The Interest?
GameStop sees surge amid retail investor interest post Roaring Kitty's return. Dive into the frenzy that shook Wall Street in 2021. Learn about the meme stock craze and its impact on hedge funds and trading platforms.
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets.
From Hype To Reality, AI Reshapes Pharmaceutical Industry Across Drug Discovery To Marketing - Stocks To Watch
Unlock the potential of AI in pharmaceuticals. With AI's help, the pharma industry could see $60B-$110B in annual economic value. Dive into the future of drug discovery and clinical development with leading players like Google, Nvidia, and Microsoft.
Fertility Solutions-Focused Progyny Stock Sinks After Soft Guidance; Analyst Says 'Can No Longer Underwrite Sustained Healthy Growth In Forecasts'
Progyny reported first-quarter sales of $278.1 million, slightly below expectations due to increased clients and covered lives. KeyBanc Capital Markets downgraded Progyny from Overweight to Sector Weight, citing concerns about revenue visibility and customer behavior.
MacroGenics Shares Tumble After Reporting Adverse Events, Multiple Deaths In Cancer Drug Trial
Latest interim data from TAMARACK Phase 2 study by MacroGenics unveils insights into vobramitamab duocarmazine targeting B7-H3 in metastatic prostate cancer. Despite responses, notable safety concerns reported.